The metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an important connection between cancer treatment and its common late effect of cardiovascular disease. Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with increased cardiovascular risk. In this review, we summarise current knowledge on the prevalence and pathophysiology of the metabolic syndrome in cancer survivors, and discuss current intervention strategies with an emphasis on new developments.

Originele taal-2English
Pagina's (van-tot)193-203
Aantal pagina's11
TijdschriftLancet Oncology
Nummer van het tijdschrift2
StatusPublished - feb.-2010

Citeer dit